The results showed that compared to low-FBX8 expression group, high-expression group had a better recurrence-free survival rate among CRC, breast cancer, and renal clear cell carcinoma (P < 0.05, P < 0.01, P < 0.05, Supplementary Fig. S8D–F). This evidence concerns the gene FBXO8 and clear cell renal carcinoma.